


Age	Infants and children <24 months of age ^{a,b}	≥24 months of age to 59 months of age	Five years of age or older
%CD4+	All ^c	≤25	NA
Absolute CD4	All ^c	≤750 cells/mm ³	≤350 cells/mm ³ (As in adults)

Infant outcomes






Questions

- Monitoring infant diagnosis coverage and transmission
 - Impact of interventions to improve diagnosis coverage? Birth testing?
 - Late transmission?
- What are the characteristics of infected infants in the context of good coverage of effective PMTCT?
- Infant outcomes in routine settings?
 - Age and disease progression at ART start
 - Retention, viral suppression
 - Co-morbidities especially neurocognitive outcomes
 - Long term outcomes

Implementation of birth EID testing in SA

Number of HIV-exposed infants delivered per month & percent with birth HIV-PCR.



Mother/infant characteristic	HIV-PCR @ 4 - 14 weeks	
	crude OR (95% CI)	adjusted OR (95% CI)
maternal age ≥35years	1.68 (1.08-2.62)	1.76 (1.11-2.78)
≥ 1 ANC visit	1.47 (0.99-2.22)	1.51 (0.99-2.30)
seroconversion during pregnancy	0.44 (0.20-0.95)	0.41 (0.18-0.91)
maternal ART < 3months	0.84 (0.61-1.16)	not included
infant < 37 weeks gestation	0.48 (0.23-1.00)	0.52 (0.26-1.05)
birth weight <2kg	0.32 (0.15-0.68)	not included
birth PCR done	0.49 (0.31-0.76)	0.53 (0.34-0.84)

Questions

- Monitoring infant diagnosis coverage and transmission
 - Impact of interventions to improve diagnosis coverage? Birth testing?
 - Late transmission?
- What are the characteristics of infected infants in the context of good coverage of effective PMTCT?
- Infant outcomes in routine settings?
 - Age and disease progression at ART start
 - Retention, viral suppression
 - Co-morbidities especially neurocognitive outcomes
 - Long term outcomes

Characteristics:

HIV – Infected Neonates


Case	GA (wks)	Birth weight (g)	Co-morbidities	Baseline CD4 cells/mm ³ / (%)	Baseline VL copies/ml (log ₁₀)	Duration of dual prophylaxis (days)	Age (days) at ART initiation	ARV regimen
1	35	1740	Congenital syphilis	1026 (22.4%)	16801 (4.23)	5	25	AZT, 3TC, KLT
2	36	2310	Congenital CMV	807 (21.41%)	636456 (5.8)	3	14	AZT, 3TC, KLT
3	36	1920	None	440 (43%)	9292 (3.92)	3	4	AZT, 3TC, KLT
4 (Twin A)	32	1380	None	1933 (50%)	6701098 (6.07)	12	13	AZT, 3TC, NVP
5 (Twin B)	32	1260	None	1933 (50%)	2962535 (6.47)	12	13	AZT, 3TC, NVP
6	38	3520	None	3776 (51.88%)	314312 (5.5)	3	35	ABC, 3TC, KLT
7	38	3260	None	1744 (49.06%)	385653 (5.49)	2	30	AZT, 3TC, KLT
8	38	3280	None	942 (39.11%)	343 (2.54)	2	None	-
9	29	1245	None	3880 (52.65%)	1146 (3.06)	11	None	-

Questions

- Monitoring infant diagnosis coverage and transmission
 - Impact of interventions to improve diagnosis coverage? Birth testing?
 - Late transmission?
- What are the characteristics of infected infants in the context of good coverage of effective PMTCT?
- Infant outcomes in routine settings?
 - Age and disease progression at ART start
 - Retention, viral suppression
 - Co-morbidities especially neurocognitive outcomes
 - Long term outcomes

Outcomes of infants initiating ART

Characteristics (n=4945)	2004-2009	2010-2012	p value
Age (months), median (IQR)	6.1 (3.8; 8.9)	5.4 (3.4; 8.4)	0.0000
WHO stage 3 or 4, n (%)	2605 (81.2%)	722 (63.4%)	0.0000
Severe Immunosuppression (WHO 2006), n (%)	2336 (89.2%)	727 (81.3%)	0.0000
WAZ category ≤ -3 (severely underweight), n (%)	1242 (44.5%)	344 (34.2%)	0.0000



Questions



- Monitoring infant diagnosis coverage and transmission
 - Impact of interventions to improve diagnosis coverage? Birth testing?
- What are the characteristics of infected infants in the context of good coverage of effective PMTCT?
- Infant outcomes in routine settings?
 - Age and disease progression at ART start
 - Retention, viral suppression
 - Co-morbidities especially neurocognitive outcomes
 - Long term outcomes